Investor Presentation

September 18, 2026 To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS Subject: Investor Presentation Dear Sir / Madam, Please find enclosed investor presentation and the same is also being uploaded on the website of the Company i.e., www.lauruslabs.com. We request you to please take the same on record. Thanking You, Yours faithfully, For Laurus Labs Limited G. Venkateswar Reddy Company Secretary & Compliance Officer Encl: A/a Investor Presentation September 2026 © 2026 Laurus Labs Ltd. Safe Harbor Statement This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, such statements reflect various assumptions concerning future developments and a number of risks, uncertainties and other important factors that could cause actual developments and results to differ materially from our expectations. These factors include, but not limited to: 1) Change in the General market and macro-economic conditions for key global markets where we operate, 2) Governmental and regulatory trends, 3) Allocations of funds by the Governments in our key global markets, 4) Successful implementation of our strategy, R&D efforts, growth & expansion plans and technological changes, 5) Movements in currency exchange and interest rates, 6) Increase in the competitive pressures and Technological developments, 7) Changes in the financial conditions of third parties dealing with us, 8) Changes in laws and regulations that apply to our customers, suppliers and Pharmaceutical industry. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results, performance or achievements of Laurus Labs Limited may vary materially from those described in the relevant forward-looking statements The information contained in this presentation is current, and if not stated otherwise, made as of the date of this presentation. The Company undertakes no obligation to update or revise any information in this presentation as a result of new information, future events or otherwise. This presentation is strictly confidential and may not be copied or disseminated, reproduced, re-circulated, re-distributed, published or advertised in any media, website or otherwise, in whole or in part, and in any manner or for any purpose without written approval from Laurus Labs Limited. Any unauthorized use, disclosure or public dissemination of information contained herein is prohibited. This presentation is for information purpose only and is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, as amended, or the rules made thereunder, the Securities and Exchange Board of India (Issue ofCapital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information fromthis presentation shall be governed by the laws of India and only the courts in Telangana, India, and no other courts, shall have jurisdiction over the same. © 2026 Laurus Labs Ltd. Investor Presentation | September 2026 2 © 2026 Laurus Labs Ltd. Investor Presentation | September 2026 F Y 2 2 F Y 2 6 F Y 2 8 Strong execution, Leading Platform & Investing for long term growth Strong Operational performance Leading Manufacturing and Accelerated CAPEX to meet growing track record Technology platform Demand, Scale and Future growth Revenue FY26 Small Flow Bio ~4300Cr >3000Cr molecule chemistry catalysis ₹6,813 Cr ▲ 23% Invested Proposed Cell & CAGR FY20-26 ▲16% ADC Peptide Gene High Continuous Spray EBITDA FY26 EBITDA Margin FY26 potency DP drying ₹1,826 Cr 26.8% 5Y 2Y ▲ 64% Guiding >30%from FY27+ Scientist 1,570+ Integrated solution API to 85% Growth Capex Formulations at Scale with Employees 8,470 global regulatory approvals Multiple large Growth 15Manufacturing sites 1425+ Quality projects (API + Peptides + FDF + Net debt / EBITDA 1.3x audits & Inspections Fermentation + CGT + ADC) 6R&D center 0Critical findings 20 years of deep commitment with Customer & Integrated solution as top priority VISION To become Leading player offering Integrated solutions in creating a healthier world Scale Integrated Quality & Innovation & Sustainability Talent Service Compliance Automation Strategic Large scale Deliver long term Cultivate high performing manufacturing sites Research-driven Stringent global Cutting edge technology Profitable growth and at Talent base and promote Framework driving (fungible) ensuring operational excellence benchmarks with platforms to solve the same time create leadership culture to Agility in responding to to deliver Value & approach to deliver One customer challenges and value for Society and secure order delivery Business execution changing customer transform along the Quality standard achieve their Environment capability needs of Scale chemistry value chain product for all markets sustainability goals Unparalleled experience on Multi-site manufacturing capability Proven track record in quality, regulatory and compliance United by Core Knowledge Innovation Excellence Care Integrity Values © 2026 Laurus Labs Ltd. Investor Presentation | September 2026 4 Integrated CDMO & CMO platform, delivering Customer value through 2 Core business divisions 1 CDMO Pre-Clinical Clinical supplies (Phase I, II and III) Commercial supplies Lifecycle management Small Molecules Specialized Modalities Animal Health and Crop Protection (Drug Substance & Drug Product) • Development & manufacturing services (RSM, • Gene technology • Anti Body Drug • Custom development & manufacturing of Intermediates, API, Drug product service) development & Conjugates (ADC) ingredients, Finished formulations manufacturing • Complex chemistry (High potent, Bio-catalysis, • Precision • Regulatory services Flow Chemistry, SDD), Regulatory services • Peptides fermentation 2 AFFORDABLE MEDICINES • Integrated capabilities across API and Formulation Development & manufacturing services, CMO supplies • Therapy focus: ARV, Oncology, Cardio, Diabetic, Gastro, CNS, Asthma and Ophthalmic © 2026 Laurus Labs Ltd. Investor Presentation | September 2026 5 Strengthening Development & Manufacturing Capabilities to meet Customer demand Small Molecules API & FDF R & D Fermentation CGT & ADC Unit 1 & 3, Vizag +3600 kL Unit 6, Vizag 1476 kL R&D 1 & Kilo lab, Hyderabad LB-1 & LB-2, Bangalore CAR-T unit-1, Mumbai +240 kL +600 treatment Unit 5, Vizag 161 kL Unit 10, Vizag (new site) R&D 2, Hyderabad Unit 7, Vizag (new site) LSPL 2, Vizag +500 kL LB-4, Vizag +400 kL (new site) CAR-T unit-2, Mumbai +2500 treatment Unit 2, Vizag +12bn units LSPL 4, Vizag +300 kL Gene Therapy/ADC, Unit 4, Vizag +2430 kL KRKA JV site, Hyderabad Hyderabad (new site) 6 Research & Development assets 15 Manufacturing assets 8800 kL 12 billion 240 kL 1570 56000 m2 Fermentation API capacity FDF capacity Fermentation capacity Research Scientists GLP lab facility Site under expansion or construction Multiple Sites -One Quality Standard © 2026 Laurus Labs Ltd. Investor Presentation | September 2026 6 Acceleration in Growth CAPEX projects across portfolio and technologies 1QFY27 CAPEX : ₹394 Cr FY22-26 CAPEX : ₹4300 Cr (19% of Revenue) (15% of Revenue) > ₹ 3,000 Cr Cumulative CAPEX over FY27 and FY28. Q1 CAPEX reached 19% of Revenue By >85% Growth CAPEX Portfolio Key projects [Showing first 8,000 characters — download PDF for full document]